Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SIRT2 transgenic over-expression does not impact lifespan in mice.
Wu LE, Fiveash CE, Bentley NL, Kang MJ, Govindaraju H, Barbour JA, Wilkins BP, Hancock SE, Madawala R, Das A, Massudi H, Li C, Kim LJ, Wong ASA, Marinova MB, Sultani G, Das A, Youngson NA, Le Couteur DG, Sinclair DA, Turner N. Wu LE, et al. Among authors: massudi h. Aging Cell. 2023 Dec;22(12):e14027. doi: 10.1111/acel.14027. Epub 2023 Nov 27. Aging Cell. 2023. PMID: 38009412 Free PMC article.
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
Cheung BB, Kleynhans A, Mittra R, Kim PY, Holien JK, Nagy Z, Ciampa OC, Seneviratne JA, Mayoh C, Raipuria M, Gadde S, Massudi H, Wong IPL, Tan O, Gong A, Suryano A, Diakiw SM, Liu B, Arndt GM, Liu T, Kumar N, Sangfelt O, Zhu S, Norris MD, Haber M, Carter DR, Parker MW, Marshall GM. Cheung BB, et al. Among authors: massudi h. Oncogene. 2021 Apr;40(13):2367-2381. doi: 10.1038/s41388-021-01712-w. Epub 2021 Mar 3. Oncogene. 2021. PMID: 33658627 Free PMC article.
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface.
Koach J, Holien JK, Massudi H, Carter DR, Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE, McCarroll JA, Liu B, Mayoh C, Keenan B, Stevenson BW, Gorman MA, Bell JL, Doughty L, Hüttelmaier S, Oberthuer A, Fischer M, Gifford AJ, Liu T, Zhang X, Zhu S, Gustafson WC, Haber M, Norris MD, Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM. Koach J, et al. Among authors: massudi h. Cancer Res. 2019 Nov 1;79(21):5652-5667. doi: 10.1158/0008-5472.CAN-19-1112. Epub 2019 Sep 9. Cancer Res. 2019. PMID: 31501192
CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM, Xie J, Gifford AJ, Wadham C, Morgan LT, Mould EVA, Fadia M, Zhai L, Massudi H, Ali ZS, Marshall GM, Lukeis RE, Fletcher JI, MacKenzie KL, Trahair TN. Fordham AM, et al. Among authors: massudi h. Br J Cancer. 2020 Sep;123(7):1101-1113. doi: 10.1038/s41416-020-0996-2. Epub 2020 Jul 20. Br J Cancer. 2020. PMID: 32684628 Free PMC article.
Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface.
Massudi H, Luo JS, Holien JK, Gadde S, Krishan S, Herath M, Koach J, Stevenson BW, Gorman MA, Venkat P, Mayoh C, Luo XQ, Parker MW, Cheung BB, Marshall GM. Massudi H, et al. Cancers (Basel). 2023 Mar 17;15(6):1822. doi: 10.3390/cancers15061822. Cancers (Basel). 2023. PMID: 36980710 Free PMC article.